Company Overview and News

 
Q1 ETF Inflows Dive at BlackRock: Tough Road Ahead?

2018-04-13 zacks
Unlike preceding quarters,net asset inflows to BlackRock Inc.’s (BLK - Free Report) ETF business dropped 46% in the first quarter to $34.6 billion from the year-ago quarter. However, despite a decline in inflows, BlackRock’s first-quarter 2018 adjusted earnings came in at $6.70 per share, which breezed past the Zacks Consensus Estimate of $6.42.
Upvote Downvote

 
Winning ETF Areas of March

2018-04-02 zacks
The month of March was all about the Fed rate hike, trade war fears, the tech market crash and a moderation in Treasury bond yields. Let’s see how investors reacted to this situation and where they parked their money in the month. The data are as of etf.com (as of March 29, 2018) (read: ETF Asset Report for First Quarter of 2017).
Upvote Downvote

 
Wining ETF Areas of March

2018-04-02 zacks
The month of March was all about the Fed rate hike, trade war fears, the tech market crash and a moderation in Treasury bond yields. Let’s see how investors reacted to this situation and where they parked their money in the month. The data are as of etf.com (as of March 29, 2018) (read: ETF Asset Report for First Quarter of 2017).
Upvote Downvote

 
Q1 ETF Asset Report: Developed Markets Win, High-Yield Loses

2018-03-29 zacks
The markets were more tensed than relaxed in the first quarter of 2018. Increasing inflationary expectations and rising rate fears pushed up bond yields and spurred equity sell-offs in late January and early February. Then, Trump-induced trade fear (thanks to his announcement of import tariffs) and a tech rout in March did the rest of the damage (read: 5 Reason Why FANG ETFs Lost Their Charm in March).
Upvote Downvote

 
ETF Month #4: Developed Markets (Ex-North America) With EFA. But Is There A Better Alternative?

2018-03-18 seekingalpha
During "ETF Month", I plan to survey a number of ETFs that have a lot of followers on Seeking Alpha, but for some reason don't have much coverage on the site. Hopefully, this will improve the visibility of Cambridge Income Laboratory and draw more members to our service, allowing me to make the newsletter better than ever. I will also be taking ETF suggestions, so do let me know if you have any ETFs on your horizon.
Upvote Downvote

 
U.S. Weekly FundFlows Insight Report: Equity Funds Attract Net New Money For The Week In Spite Of Fears Of Inflation And A Trade War

2018-03-16 seekingalpha
For the first week in four, investors were net redeemers of fund assets (including those of conventional funds and ETFs), withdrawing $291 million. However, the headline number was a bit misleading. While fund investors were net redeemers of money market funds (-$24.2 billion), they padded the coffers of equity funds (+$20.4 billion), taxable bond funds (+$3.2 million), and municipal bond funds (+$339 million) for the fund flows week ended March 14, 2018.
Upvote Downvote

 
IEFA / iShares Core MSCI EAFE ETF / BlackRock Inc. - null (Passive Investment)

2018-03-08 sec.gov
us46432f8427_030518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) ISHARES CORE MSCI EAFE ETF -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 46432F842 -------------------------------------------------------- (CUSIP Number) February 28, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of th
Upvote Downvote

 
IEFA / iShares Core MSCI EAFE ETF / BlackRock Inc. - null (Passive Investment)

2018-03-08 sec.gov
us46432f8427_030518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) ISHARES CORE MSCI EAFE ETF -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 46432F842 -------------------------------------------------------- (CUSIP Number) February 28, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of th
Upvote Downvote

1
Inside February ETF Asset Report

2018-03-02 zacks
February 2018 will be remembered for the brake that the Trump Rally hit after a long and smooth journey. Several market watchers persistently warned of overvaluation and investors have showed amazing patience so far. But the U.S. market crashed to start February.
Upvote Downvote

 
The Last ETF To Buy For Your Core Portfolio

2018-02-28 seekingalpha
Creating a core portfolio of ETFs is a quick and simple way to manage your investments and provides a higher expected return for a given level of volatility.
Upvote Downvote

 
Weekly ETF Roundup: International & Bond Win, US Equity Lags

2018-02-26 zacks
Although the U.S. stock market ended the week on a positive note, concerns over speedy rates hike unnerved investors. This is especially true as a stronger economy, signs of a pickup in inflation and Fed minutes could compel the Fed to raise interest rates more times than three-liftoffs penciled for this year. Against such a backdrop, ETFs overall gathered about $4.9 billion capital last week, with international equity ETFs leading the way higher with $4.
Upvote Downvote

 
The Fourth ETF To Buy For Your Core Portfolio

2018-02-23 seekingalpha
Creating a core portfolio of ETFs is a quick and simple way to manage your investments and provides a higher expected return for a given level of volatility.
Upvote Downvote

1
U.S. Weekly FundFlows Insight Report: Despite 4-Day Stock Market Rally, Fund Investors Are Net Redeemers For The Week

2018-02-16 seekingalpha
For the second week in three, investors were net sellers of fund assets (including those of conventional funds and ETFs), withdrawing $14.1 billion. Despite a turnaround in the equity market, fund investors were net redeemers for the week of equity funds (-$4.6 billion), taxable bond funds (-$7.8 billion), municipal bond funds (-$443 million), and money market funds (-$1.3 billion).
Upvote Downvote

 
January ETF Asset Report: S&P 500 Wins, High-Yield Loses

2018-02-02 zacks
The month of January was all about Trump bump, cheering the tax reform, reassuring earnings, global economic growth and rising Treasury bond yields. Overall, markets remained upbeat though equities slipped at the end (read: Is it Time to Buy the Dip with ETFs?).
Upvote Downvote

 
U.S. Weekly FundFlows Insight Report: Fund Investors Pad The Coffers Of Long-Term Assets For The Week

2018-01-19 seekingalpha
For the second week in three, investors were net sellers of fund assets (including those of conventional funds and ETFs), withdrawing $9.6 billion. However, the headline numbers were a little misleading. Fund investors were net redeemers of money market funds, withdrawing $22.3 billion, but were net purchasers of long-term assets, padding the coffers of equity funds (+$9.1 billion), taxable bond funds (+$2.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 46432F842